THC-CBD Treatment Dramatically Reduces Agitation in Dementia Trial
Reported byGeorgetown University Medical Center ↗·Sourced by Goodlede
In the LiBBY trial, a specially formulated THC-CBD medication reduced agitation in 120 hospice-eligible dementia patients across 10 U.S. medical centers, with nearly 90% showing improvement at 12 weeks compared to placebo—a response rate unusually high for dementia behavioral interventions.
The formulation is a medical preparation distinct from commercial cannabis products. Results from a first-of-its-kind trial; replication needed.
Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.
Read the full story at Georgetown University Medical Center
Read original story ↗More good news, verified daily.
Goodlede covers positive developments across science, nature, rights, and human achievement — verified before they appear. No hype, no roundups, no PR wires.
© 2026 Wag Media, LLC
More from Goodlede